Transition Therapeutics Profile

1.93
CAD 0.00  0.00%
0%
0%

Transition Therapeutics Summary

Transition Therapeutics (TTH) is traded on Toronto Stock Exchange in Canada. It is located in Toronto, ON MG L and employs 18 people. The company currently falls under '' category with current market capitalization of 0. Transition Therapeutics has 38.8 M outstanding shares of which 700 shares are at this time shorted by private and institutional investors with about 0.0 days to cover all short positions. TRANSITION THERAP has accumulated about 24.77 M in cash with (25.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64.
Check Transition Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 1.93HorizonTargetOdds Above 1.93
?%30 days 1.93 ?%
Based on normal probability distribution, the odds of Transition Therapeutics to move above current price in 30 days from now is about 0.0% (This Transition Therapeutics probability density function shows the probability of Transition Therapeutics Stock to fall within a particular range of prices over 30 days) .

Key Fundamentals

Transition Therapeutics Against Markets

Current Ratings

Transition Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
75 
Equity ratings for Transition Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications primarily in Canada. more
NameTransition Therapeutics
Chairman and CEOTony CruzView All
Macroaxis Advice
InstrumentCanada Stock View All
Business AddressToronto, ON MG L
ExchangeToronto Stock Exchange
BenchmarkDOW
Websitewww.transitiontherapeutics.com
Contact Number416 260 7770
CurrencyCAD - Canadian Dollar

Diversify with Transition Therapeutics

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Transition Therapeutics to your portfolio

Directors

Transition Therapeutics Corporate Directors
Christopher Henley Independent Director
Gary Pace Independent Director, Ph.D
Paul Baehr Independent Director
Also please take a look at World Market Map. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.